Top in cardiology: SGLT2 inhibitor therapy; coordinated cardiovascular care
Click Here to Manage Email Alerts
Patients with heart failure who received an SGLT2 inhibitor were less likely to experience sudden cardiac death compared with those who received placebo, according to a study in Clinical Cardiology.
“The decreased incidence of sudden cardiac death in patients with [heart failure] receiving SGLT2 inhibitor therapy is directly concordant with studies demonstrating that SGLT2 inhibitor therapy has a profound impact on CV death and heart failure hospitalizations in patients with heart failure regardless of ejection fraction,” Connor Oates, MD, a cardiovascular disease fellow with MedStar Heart and Vascular Institute and Georgetown University-Washington Hospital Center, and colleagues wrote.
It was the top story in cardiology last week.
Another top story was about a coordinated intervention in cardiology clinics that boosted prescriptions of guideline-recommended CVD and diabetes therapies. Researchers said they plan to scale this intervention across more cardiology clinics.
Read these and more top stories in cardiology below:
SGLT2 inhibitor therapy reduces sudden cardiac death risk in heart failure
SGLT2 inhibitor therapy in patients with heart failure is associated with a significantly lower incidence of sudden cardiac death vs. placebo, with the benefit persisting independent of other guideline-directed medical therapies. Read more.
Coordinated care can improve prescribing practices of recommended diabetes, CVD therapies
Implementing a coordinated care intervention in U.S. cardiology clinics led to a fourfold increase in the prescription of three groups of guideline-recommended therapies in adults with type 2 diabetes and atherosclerotic CVD. Read more.
Polypill for blood pressure lowering may improve adherence and reduce mortality
A renin-angiotensin system combination polypill to treat high BP was associated with improved adherence and lower all-cause mortality and cardiovascular event rates vs. taking multiple pills, researchers reported. Read more.
AI identifies reasons for statin nonuse in patients with diabetes at a single center
A deep learning model utilized unstructured electronic health record data to identify specific patient-, physician- and system-level reasons for statin nonuse among patients with diabetes, researchers reported. Read more.
Moderate exercise may be safe for patients with statin-related muscle pain
In a short-term study, researchers found no effect of statin therapy on self-reported muscle injury or symptoms after moderate exercise, regardless of whether patients were symptomatic at baseline. Read more.